Indivior discontinues sales of Perseris
Indivior will continue supplying Perseris despite ending promotional efforts
Indivior has discontinued all sales and marketing activities for its schizophrenia drug, Perseris. The decision was prompted by increased payor management impacts and a highly competitive market, which the company believes make the product financially unviable.
Indivior will continue to supply Perseris for the foreseeable future to avoid disruption to patient care but will no longer deploy a dedicated sales force.
As a result, the company expects to reduce headcount by approximately 130 employees. Indivior does not anticipate material impacts on its other marketed products because of this decision.
Why did Indivior discontinue Perseris marketing?
Indivior cited increased payor management pressures and a highly competitive market, making Perseris financially unviable.
Will Perseris still be available to patients?
Yes, Indivior will continue supplying Perseris to avoid disruption to patient care, despite ending promotional efforts.
How many jobs will be affected by the Perseris decision?
Indivior expects to reduce headcount by approximately 130 employees as a result of discontinuing Perseris marketing.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.